CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The new online Learning Center with new content can still be found under the “Training” folder on ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...